Shares of Quest Diagnostics Inc. (NYSE:DGX) have been given an average rating of “Hold” by the sixteen analysts that are presently covering the company. Three research analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation and two have given a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $84.25.

Several brokerages recently issued reports on DGX. Mizuho boosted their price target on Quest Diagnostics from $86.00 to $88.00 and gave the company a “neutral” rating in a research report on Friday, October 21st. Canaccord Genuity set a $90.00 price target on Quest Diagnostics and gave the company a “buy” rating in a research report on Monday, November 14th. Barclays PLC set a $85.00 price target on Quest Diagnostics and gave the company a “hold” rating in a research report on Monday, November 14th. Bank of America Corp. restated a “sell” rating and issued a $78.00 price target on shares of Quest Diagnostics in a research report on Monday, November 14th. Finally, Zacks Investment Research upgraded Quest Diagnostics from a “hold” rating to a “buy” rating and set a $93.00 price target on the stock in a research report on Wednesday, September 21st.

ILLEGAL ACTIVITY WARNING: “Quest Diagnostics Inc. (DGX) Given Average Recommendation of “Hold” by Brokerages” was originally reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark and copyright legislation. The correct version of this news story can be read at https://www.thecerbatgem.com/2016/11/28/quest-diagnostics-inc-dgx-given-average-recommendation-of-hold-by-brokerages.html.

Institutional investors have recently added to or reduced their stakes in the company. Itau Unibanco Holding S.A. bought a new stake in shares of Quest Diagnostics during the third quarter valued at about $110,000. Financial Architects Inc increased its position in shares of Quest Diagnostics by 6.4% in the second quarter. Financial Architects Inc now owns 1,476 shares of the company’s stock valued at $120,000 after buying an additional 89 shares during the last quarter. TLP Group LLC purchased a new position in shares of Quest Diagnostics during the third quarter valued at $130,000. Pinkerton Retirement Specialists LLC increased its position in shares of Quest Diagnostics by 792.4% in the second quarter. Pinkerton Retirement Specialists LLC now owns 1,651 shares of the company’s stock valued at $134,000 after buying an additional 1,466 shares during the last quarter. Finally, Integrated Investment Consultants LLC increased its position in shares of Quest Diagnostics by 10.4% in the second quarter. Integrated Investment Consultants LLC now owns 1,869 shares of the company’s stock valued at $152,000 after buying an additional 176 shares during the last quarter. 86.81% of the stock is owned by institutional investors.

Shares of Quest Diagnostics (NYSE:DGX) traded down 0.36% during mid-day trading on Monday, hitting $88.00. The company had a trading volume of 410,565 shares. The firm has a 50-day moving average price of $83.41 and a 200 day moving average price of $82.13. The firm has a market capitalization of $12.20 billion, a P/E ratio of 18.68 and a beta of 0.62. Quest Diagnostics has a 12 month low of $59.66 and a 12 month high of $88.43.

Quest Diagnostics (NYSE:DGX) last announced its earnings results on Thursday, October 20th. The company reported $1.37 earnings per share for the quarter, topping the consensus estimate of $1.35 by $0.02. Quest Diagnostics had a net margin of 9.01% and a return on equity of 14.57%. The business earned $1.89 billion during the quarter, compared to the consensus estimate of $1.53 billion. During the same quarter in the prior year, the firm earned $1.28 earnings per share. The business’s quarterly revenue was up .3% compared to the same quarter last year. On average, equities research analysts forecast that Quest Diagnostics will post $5.10 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 25th. Investors of record on Tuesday, January 10th will be paid a $0.45 dividend. This represents a $1.80 dividend on an annualized basis and a yield of 2.04%. This is a positive change from Quest Diagnostics’s previous quarterly dividend of $0.40. Quest Diagnostics’s dividend payout ratio is presently 34.04%.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Company’s Diagnostic Information Services business develops and delivers diagnostic testing information and services to patients, physicians, health plans, hospitals, accountable care organizations (ACOs), integrated delivery networks (IDNs), other commercial laboratories, employers and others.

5 Day Chart for NYSE:DGX

Receive News & Stock Ratings for Quest Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Inc. and related stocks with our FREE daily email newsletter.